TransCelerate Selects Cognizant for Shared Investigator Platform

Article

Applied Clinical Trials

Cognizant announced that it has been selected by TransCelerate BioPharma Inc. to develop a subscription-based platform

Cognizant announced that it has been selected by TransCelerate BioPharma Inc. to develop a subscription-based platform to enable the pharmaceutical industry to bring standardization and consistency to clinical trials.

The Shared Investigator Platform, which will be built as an 'industry utility' and is built to enhance organizational productivity by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy, and reducing study start-up time. It will also help pharmaceutical companies to improve quality, regulatory compliance, process visibility, and capacity, while reducing investigator efforts related to training, document exchange, and support. In the future, the platform may provide regulators with an efficient electronic audit process and better insight into clinical trials.

Read the full release here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.